BioSpace News Archive

APOL1 kidney disease PerlQuest co-development partnership with Rambam Medical Center in Haifa, Israel, and the laboratory of leading nephrologist and kidney disease researcher Dr. Karl Skorecki.

Technavio analysts forecast the global neurostimulation devices market to grow at a CAGR of nearly 11% during the forecast period, according to their latest market research report.

InstaDose Pharma has over 200,000 farmers harvesting cannabis out of the Democratic Republic of the Congo on over 100,000 hectares of land.

Orthofix Medical Inc. announced that President and Chief Executive Officer Brad Mason will present at the J.P. Morgan Healthcare Conference in San Francisco on Thursday, January 10, 2019 at 7:30 a.m. PT

The Trade Group for Kratom Now Reaching Out to Key Lawmakers in Georgia; “90 Percent of Issues” Will Require Involving Manufacturing, Distributors and Retailers in Georgia Process

Harpoon Therapeutics, Inc announced that it has filed a registration statement on Form S-1 with the U.S. Securities and Exchange Commission (the “SEC”) relating to a proposed initial public offering of its common stock

Developing a continuous CSF clearance device for treatment of ALS and PSP patients

Dr. Reddy’s Laboratories Ltd. today announced the launch of Sevelamer Carbonate for Oral Suspension, in 0.8 g and 2.4 g packets, a therapeutic equivalent generic version of Renvela (sevelamer carbonate) for Oral Suspension, approved by the U.S. Food and Drug Administration (USFDA).

Sesen Bio, Inc. today announced that company management will host a conference call on Thursday, Jan. 3, 2018 at 8:30 a.m. ET to review updated data from its Phase 3 VISTA Trial of Vicinium™ for the treatment of patients with high-grade non-muscle invasive bladder cancer who have been previously treated with bacillus Calmette-Guérin.

Company plans to expand its WeedPass rewards program to San Francisco and Phoenix markets in early 2019